JPMorgan Chase & Co. Increases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

JPMorgan Chase & Co. lifted its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 108.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 335,741 shares of the biopharmaceutical company's stock after buying an additional 175,019 shares during the period. JPMorgan Chase & Co. owned approximately 0.58% of Vanda Pharmaceuticals worth $1,608,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of VNDA. Geode Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 7.1% during the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company's stock worth $6,689,000 after acquiring an additional 94,870 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Vanda Pharmaceuticals by 4.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock worth $3,925,000 after buying an additional 38,449 shares during the last quarter. Monaco Asset Management SAM lifted its position in Vanda Pharmaceuticals by 92.8% during the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock valued at $1,879,000 after purchasing an additional 188,836 shares during the period. American Century Companies Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 2.1% in the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company's stock valued at $1,438,000 after buying an additional 6,079 shares during the period. Finally, Barclays PLC raised its position in Vanda Pharmaceuticals by 128.2% during the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock valued at $722,000 after acquiring an additional 86,677 shares in the last quarter. Institutional investors own 88.14% of the company's stock.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average price of $4.46 per share, with a total value of $44,600.00. Following the completion of the purchase, the chief executive officer now owns 2,331,730 shares in the company, valued at $10,399,515.80. This trade represents a 0.43 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 32,000 shares of company stock valued at $151,180 over the last 90 days. 8.90% of the stock is owned by company insiders.

Vanda Pharmaceuticals Trading Down 0.4 %

NASDAQ:VNDA traded down $0.02 during trading hours on Thursday, hitting $4.49. The company had a trading volume of 71,337 shares, compared to its average volume of 764,369. The company has a 50-day moving average of $4.56 and a 200 day moving average of $4.67. The company has a market cap of $264.61 million, a P/E ratio of -14.03 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a 1 year low of $3.85 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million during the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. On average, analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on VNDA. StockNews.com started coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, April 1st.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.